Quantoom Benchmarking Visit

The benchmarking visit to QT, a subsidiary of Univercells that also includes UNIZIMA and Exothera, focused on evaluating the R&D potential of widening partners in vaccine development, particularly mRNA technology. The visit, held on October 7-8, 2024, included hybrid meetings and workshops with participants from IPT, DA, TK, CI, and IP, along with staff from the Univercells subsidiaries. The program featured four workshop sessions and two R&D lab visits, including demos of the QT N’tensify platforms for mRNA production. Each partner provided an overview of their current R&D strategies in mRNA vaccine development and their future training needs for the VISION project.